![]() |
市场调查报告书
商品编码
1494760
表皮生长因子受体 (EGFR) 抑制剂到 2030 年的全球市场预测:按类型、药物类型、给药方法、分销管道、应用、最终用户和地区进行分析Epidermal Growth Factor Receptor Inhibitors Market Forecasts to 2030 - Global Analysis By Type, Drug Type, Mode of Administration, Distribution Channel, Application, End User and By Geography |
根据Stratistics MRC预测,2024年全球表皮生长因子受体(EGFR)抑制剂市场规模将达141亿美元,预测期内复合年增长率为14.2%,预计2030年将达314亿美元。
表皮生长因子受体 (EGFR) 抑制剂是一种针对錶皮生长因子受体(一种存在于细胞表面的蛋白质)的药物。 EGFR 参与细胞生长和分裂,其过度活性与某些癌症,特别是肺癌和大肠癌的发生和进展有关。 GFR 抑制剂可单独使用或与化疗或放射线治疗等其他癌症治疗方法合併用于治疗多种癌症。
据美国国立卫生研究院称,近年来,美国各类主要癌症的新病例显着增加,包括肺癌、大肠直肠癌和乳腺癌。 2020年,美国预计将有180万人被诊断出罹患癌症,606,520人将死于该疾病。
扩大标靶治疗的采用
市场正在经历标靶治疗的快速采用,反映了不断变化的治疗模式。标靶治疗透过特异性针对癌细胞并最大限度地减少对健康组织的损害来提高抗癌的精确度。这种模式转移是由研究和开发的进步以及对促进癌症进展的分子途径的深入了解所推动的。随着个人化治疗方法普及普遍,随着对个别患者的个人化治疗的转变,市场有望实现显着成长。
替代治疗的可用性
市场面临着适应替代疗法的挑战。儘管 EGFR 抑制剂有效,但免疫疗法和标靶治疗等替代疗法正在相互竞争。此外,EGFR 抑制剂的抗药性和副作用也增加了复杂性。确保替代疗法的可用性、可负担性和患者意识仍然是重要的障碍。市场必须适应,将这些治疗方法整合到治疗方案中,并满足患者的特定需求以获得最佳结果。
癌症发生率上升
市场上有一个令人担忧的趋势:癌症发生率上升。儘管Erlotinib和Gefitinib等 EGFR 抑制剂的治疗取得了进展,但依赖这些疗法的癌症病例的发生率仍在增加。这可能表明 EGFR 诱发的癌症盛行率增加,或者先前对这些药物有反应的患者可能出现抗药性。这些趋势凸显了继续研究癌症生物学和开发创新治疗策略的必要性。
昂贵的治疗费用
该市场面临着治疗成本高昂的挑战,为患者的取得造成了障碍。儘管它们在治疗某些癌症方面有效,但抑制剂的经济负担限制了它们的普及。这个成本因素凸显了相关人员需要共同努力开发更便宜的选择并探索津贴途径,以确保公平地获得挽救生命的治疗。
COVID-19 的爆发对市场产生了重大影响,扰乱了製造、供应链和临床试验。关闭和限制阻碍了患者进入医疗机构,影响了诊断和治疗的开始。然而,随着远端医疗和远端监控的引入,保持了一定的连续性。市场出现了需求波动,并转向优先考虑基本治疗。儘管面临挑战,但持续的研究和开发旨在在大流行的挑战中满足新的需求并优化治疗结果。
预计联合治疗领域在预测期内将是最大的。
预计联合治疗领域在预测期内将是最大的。透过同时针对多个途径,这些疗法旨在提高疗效并克服抗药性机制。 EGFR 抑制剂与化疗、免疫疗法和其他标靶药物的联合治疗正在进行研究,并在多种癌症类型中显示出前景。这些方法为个人化治疗方法提供了新途径,并可透过解决异质性肿瘤特征和适应性抗药性机制来改善患者预后。
在预测期内,大肠直肠癌领域的复合年增长率最高。
由于标靶治疗的进步,预计结直肠癌领域在预测期内将出现最高的复合年增长率。这些抑制剂,如Cetuximab和Panitumumab,透过抑制 EGFR 讯号途径,在改善患者预后方面显示出有希望的结果。由于全球大肠直肠癌盛行率不断上升以及对个人化治疗的需求不断增加,预计 EGFR 抑制剂市场将显着成长。
由于癌症发病率增加和标靶治疗的进步等因素,预计北美在预测期内将占据最大的市场占有率。这些抑制剂专注于精准医疗,在肺癌和大肠癌等多种癌症的治疗中发挥重要作用。该地区的主要公司继续投资于研发,旨在推出创新治疗方法。
预计亚太地区在预测期内将维持最高的复合年增长率。该地区经常使用 EGFR 抑制剂治疗的癌症(例如肺癌和大肠癌)的发生率正在增加。人们对癌症的认识不断提高,筛检计画得到加强,从而能够及早发现癌症,从而使更多的患者有资格接受标靶治疗。此外,不断上升的医疗保健成本和意识进一步推动市场成长,创造了以持续的临床试验和产品发布为特征的竞争格局。
According to Stratistics MRC, the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is accounted for $14.1 billion in 2024 and is expected to reach $31.4 billion by 2030 growing at a CAGR of 14.2% during the forecast period. Epidermal Growth Factor Receptor (EGFR) inhibitors are a class of medications that target the epidermal growth factor receptor, a protein found on the surface of cells. EGFR is involved in cell growth and division, and its overactivity is associated with the development and progression of certain types of cancer, particularly lung cancer and colorectal cancer. GFR inhibitors are used in the treatment of various cancers, either alone or in combination with other cancer therapies, such as chemotherapy or radiation therapy.
According to the NIH, the new cases of various types of major cancers, such as lung cancer, colorectal cancer, and breast cancer, in the US have increased significantly in recent years. In 2020, an estimated 1.8 million new cases of cancer were diagnosed in the US, and 606,520 people will die from the disease.
Growing adoption of targeted therapies
The market is witnessing a surge in adoption of targeted therapies, reflecting an evolving treatment landscape. Targeted therapies offer precision in combating cancer by specifically targeting cancer cells, minimizing damage to healthy tissue. This paradigm shift is driven by advancements in research and development, alongside increasing understanding of molecular pathways driving cancer progression. With personalized treatment approaches gaining traction, the market is poised for substantial growth as it moves towards tailored therapies for individual patients.
Availability of alternative therapies
The market faces challenges in accommodating alternative therapies. Despite the effectiveness of EGFR inhibitors, alternative treatments like immunotherapy and targeted therapies pose competition. Additionally, resistance to EGFR inhibitors and adverse effects contribute to the complexity. Ensuring accessibility, affordability, and patient awareness of alternative therapies remain key hurdles. The market must adapt by integrating these therapies into treatment protocols and addressing patient-specific needs for optimal outcomes.
Rising cancer rates
The market has seen a concerning trend of rising cancer rates. Despite advancements in treatment utilizing EGFR inhibitors, such as Erlotinib and Gefitinib, the incidence of cancer cases reliant on these therapies has increased. This may indicate either a growing prevalence of EGFR-driven cancers or potential resistance development in patients previously responsive to these drugs. Such trends underscore the need for continued research into cancer biology and the development of innovative therapeutic strategies.
High cost of treatment
The market faces challenges due to high treatment costs, posing a barrier to accessibility for patients. Despite their efficacy in treating certain cancers, the financial burden associated with these inhibitors limits their widespread adoption. This cost factor underscores the need for collaborative efforts among stakeholders to develop more affordable options or explore avenues for subsidization to ensure equitable access to life-saving treatments.
The COVID-19 pandemic significantly impacted the Market, causing disruptions in manufacturing, supply chains, and clinical trials. Lockdowns and restrictions hindered patient access to healthcare facilities, affecting diagnosis and treatment initiation. However, with the adoption of telemedicine and remote monitoring, some continuity was maintained. The market witnessed fluctuations in demand, with a shift towards prioritizing essential treatments. Despite challenges, ongoing research and development efforts persisted, aiming to address emerging needs and optimize therapeutic outcomes amidst the pandemic's challenges.
The combination therapies segment is expected to be the largest during the forecast period
The combination therapies segment is expected to be the largest during the forecast period. By targeting multiple pathways simultaneously, these therapies aim to enhance efficacy and overcome resistance mechanisms. Combinations of EGFR inhibitors with chemotherapy, immunotherapy, and other targeted agents are being explored, showing potential in various cancer types. Such approaches offer new avenues for personalized treatment regimens and may improve patient outcomes by addressing heterogeneous tumor profiles and adaptive resistance mechanisms.
The colorectal cancer segment is expected to have the highest CAGR during the forecast period
The colorectal cancer segment is expected to have the highest CAGR during the forecast period driven by advancements in targeted therapies. These inhibitors, such as cetuximab and panitumumab, have shown promising results in improving patient outcomes by inhibiting EGFR signaling pathways. With increasing prevalence of colorectal cancer globally, coupled with growing demand for personalized treatment approaches, the EGFR inhibitors market is poised for significant growth.
North America is projected to hold the largest market share during the forecast period driven by factors such as increasing cancer prevalence and advancements in targeted therapies. With a focus on precision medicine, these inhibitors play a crucial role in treating various cancers, including lung and colorectal cancer. Key players in the region continue to invest in research and development, aiming to introduce innovative therapies.
Asia Pacific is projected to hold the highest CAGR over the forecast period. The region has witnessed a rise in the incidence of cancer, including lung cancer and colorectal cancer, which are often treated with EGFR inhibitors. Increasing awareness about cancer and the availability of screening programs have led to earlier detection of cancers, resulting in more patients being eligible for targeted therapies. Moreover, rising healthcare expenditure and awareness further bolster market growth, fostering a competitive landscape characterized by ongoing clinical trials and product launches.
Key players in the market
Some of the key players in Epidermal Growth Factor Receptor (EGFR) Inhibitors market include Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Amgen Inc, Eli Lilly and Company, OSI Pharmaceuticals Inc, Johnson & Johnson, Genentech, Inc, Pfizer, AstraZeneca PLC, Bayer AG, AbbVie, Bristol Myers Squibb, Teva Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim and Regeneron Pharmaceuticals.
In May 2023, Eli Lilly and Innovent Biologics, Inc. jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT(R) (sintilimab injection) in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) in patients with epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC).
In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.